Cargando…

A pilot randomised controlled trial of metacognitive therapy for prolonged grief

OBJECTIVES: Prolonged grief disorder is associated with significant distress and impairment and thus efforts to improve treatments are essential. The present pilot study tested the efficacy and feasibility of group Metacognitive Grief Therapy (MCGT) designed specifically for prolonged grief symptoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Wenn, Jenine Anne, O’Connor, Moira, Kane, Robert T, Rees, Clare Samantha, Breen, Lauren J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340007/
https://www.ncbi.nlm.nih.gov/pubmed/30782672
http://dx.doi.org/10.1136/bmjopen-2017-021409
_version_ 1783388726299197440
author Wenn, Jenine Anne
O’Connor, Moira
Kane, Robert T
Rees, Clare Samantha
Breen, Lauren J
author_facet Wenn, Jenine Anne
O’Connor, Moira
Kane, Robert T
Rees, Clare Samantha
Breen, Lauren J
author_sort Wenn, Jenine Anne
collection PubMed
description OBJECTIVES: Prolonged grief disorder is associated with significant distress and impairment and thus efforts to improve treatments are essential. The present pilot study tested the efficacy and feasibility of group Metacognitive Grief Therapy (MCGT) designed specifically for prolonged grief symptomatology to reduce the psychological distress and impaired function resulting from bereavement. DESIGN/PARTICIPANTS: Twenty-two bereaved adult participants with prolonged grief symptomatology were randomised to a wait-list control (n=10) or an intervention condition (n=12) with a 3-month and 6-month follow-up. The wait-list control group was offered treatment after the post-test assessment. INTERVENTION: Participants attended six group MCGT sessions that ran for 2 hours per week. OUTCOME MEASURES: A primary outcome measure of prolonged grief symptomatology and secondary outcome measures of depression, anxiety, rumination, metacognitive beliefs and quality of life were taken pretreatment and post-treatment for both groups and at the 3-month and 6-month follow-up for the intervention group. A Generalised Linear Mixed Model was used to assess treatment efficacy. RESULTS: Post-treatment intent-to-treat analyses showed MCGT reduced prolonged grief symptomatology (Cohen’s d=1.7), depression (d=1.3), anxiety (d=0.8), stress (d=1.0), rumination (d=0.9) and increased quality of life (d=0.6), and these effects were maintained at the 3-month and 6-month follow-ups. No prepost between-group differences were found in metacognitive beliefs. However, a large significant effect was identified at the 3-month and 6-month follow-ups (d=1.0). CONCLUSION: The results show promise for the utility of group MCGT for reducing psychological distress and promoting quality of life. Additionally, the results underscore the need for a full randomised controlled trial of group MCGT, which may be an important addition to the treatment armamentarium available to support people with prolonged grief. TRIAL REGISTRATION NUMBER: ACTRN12613001270707; Results. ORIGINAL PROTOCOL: BMJ Open 2015;5:e007221. doi:10.1136/bmjopen-2014-007221
format Online
Article
Text
id pubmed-6340007
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-63400072019-02-02 A pilot randomised controlled trial of metacognitive therapy for prolonged grief Wenn, Jenine Anne O’Connor, Moira Kane, Robert T Rees, Clare Samantha Breen, Lauren J BMJ Open Mental Health OBJECTIVES: Prolonged grief disorder is associated with significant distress and impairment and thus efforts to improve treatments are essential. The present pilot study tested the efficacy and feasibility of group Metacognitive Grief Therapy (MCGT) designed specifically for prolonged grief symptomatology to reduce the psychological distress and impaired function resulting from bereavement. DESIGN/PARTICIPANTS: Twenty-two bereaved adult participants with prolonged grief symptomatology were randomised to a wait-list control (n=10) or an intervention condition (n=12) with a 3-month and 6-month follow-up. The wait-list control group was offered treatment after the post-test assessment. INTERVENTION: Participants attended six group MCGT sessions that ran for 2 hours per week. OUTCOME MEASURES: A primary outcome measure of prolonged grief symptomatology and secondary outcome measures of depression, anxiety, rumination, metacognitive beliefs and quality of life were taken pretreatment and post-treatment for both groups and at the 3-month and 6-month follow-up for the intervention group. A Generalised Linear Mixed Model was used to assess treatment efficacy. RESULTS: Post-treatment intent-to-treat analyses showed MCGT reduced prolonged grief symptomatology (Cohen’s d=1.7), depression (d=1.3), anxiety (d=0.8), stress (d=1.0), rumination (d=0.9) and increased quality of life (d=0.6), and these effects were maintained at the 3-month and 6-month follow-ups. No prepost between-group differences were found in metacognitive beliefs. However, a large significant effect was identified at the 3-month and 6-month follow-ups (d=1.0). CONCLUSION: The results show promise for the utility of group MCGT for reducing psychological distress and promoting quality of life. Additionally, the results underscore the need for a full randomised controlled trial of group MCGT, which may be an important addition to the treatment armamentarium available to support people with prolonged grief. TRIAL REGISTRATION NUMBER: ACTRN12613001270707; Results. ORIGINAL PROTOCOL: BMJ Open 2015;5:e007221. doi:10.1136/bmjopen-2014-007221 BMJ Publishing Group 2019-01-09 /pmc/articles/PMC6340007/ /pubmed/30782672 http://dx.doi.org/10.1136/bmjopen-2017-021409 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Mental Health
Wenn, Jenine Anne
O’Connor, Moira
Kane, Robert T
Rees, Clare Samantha
Breen, Lauren J
A pilot randomised controlled trial of metacognitive therapy for prolonged grief
title A pilot randomised controlled trial of metacognitive therapy for prolonged grief
title_full A pilot randomised controlled trial of metacognitive therapy for prolonged grief
title_fullStr A pilot randomised controlled trial of metacognitive therapy for prolonged grief
title_full_unstemmed A pilot randomised controlled trial of metacognitive therapy for prolonged grief
title_short A pilot randomised controlled trial of metacognitive therapy for prolonged grief
title_sort pilot randomised controlled trial of metacognitive therapy for prolonged grief
topic Mental Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340007/
https://www.ncbi.nlm.nih.gov/pubmed/30782672
http://dx.doi.org/10.1136/bmjopen-2017-021409
work_keys_str_mv AT wennjenineanne apilotrandomisedcontrolledtrialofmetacognitivetherapyforprolongedgrief
AT oconnormoira apilotrandomisedcontrolledtrialofmetacognitivetherapyforprolongedgrief
AT kanerobertt apilotrandomisedcontrolledtrialofmetacognitivetherapyforprolongedgrief
AT reesclaresamantha apilotrandomisedcontrolledtrialofmetacognitivetherapyforprolongedgrief
AT breenlaurenj apilotrandomisedcontrolledtrialofmetacognitivetherapyforprolongedgrief
AT wennjenineanne pilotrandomisedcontrolledtrialofmetacognitivetherapyforprolongedgrief
AT oconnormoira pilotrandomisedcontrolledtrialofmetacognitivetherapyforprolongedgrief
AT kanerobertt pilotrandomisedcontrolledtrialofmetacognitivetherapyforprolongedgrief
AT reesclaresamantha pilotrandomisedcontrolledtrialofmetacognitivetherapyforprolongedgrief
AT breenlaurenj pilotrandomisedcontrolledtrialofmetacognitivetherapyforprolongedgrief